NeuLogiq® Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Cumulus

More Like This

PR Newswire associated0

NeuLogiq® Platform Confirms Electrophysiological Marker of Target Engagement in Patients with Major Depressive Disorder

PR Newswire associated0

Cumulus Neuroscience Presents Data at the International Society for CNS Clinical Trials and Methodology Autumn Conference and the 38th European College of Neuropsychopharmacology Congress

PR Newswire associated0

Cumulus Neuroscience Presents Data at AD/PD™ 2025 Annual Meeting

PR Newswire associated0

Cumulus Neuroscience Presents Data at CTAD 2025 Annual Meeting

PR Newswire associated0

Cumulus Neuroscience Presents Data at AAIC 2024 Annual Meeting and Technology and Dementia Preconference

PR Newswire associated0

Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.

PR Newswire associated0

Cumulus Neuroscience Presents Data at AAIC 2025 Annual Meeting and Technology and Dementia Preconference

PR Newswire associated0

QuantalX Secures FDA Clearance for its breakthrough Delphi stimulator, advancing direct brain health diagnosis at the point of care